Breaking News, Financial News

4Q Financial Reports: Bristol-Myers Squibb

Bristol-Myers Squibb

4Q Revenues: $5 billion (-3%)

4Q Earnings: $499 million (+259%)

FY Revenues: $19 billion (-1%)

FY Earnings: $3 billion (+25%)

Comments: Orencia was approved for the treatment of RA symptoms in the quarter. Worldwide pharmaceutical sales decreased 3% to $4 billion in the quarter. Sales of Plavix increased 11% to $1 billion in the quarter; sales of Avapro/Avalide increased 7% to $277 million in the quarter; total revenue for Abilify increased 17% to $224 million. R&D spend was up 14% in the quarter to $775 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters